The NIA Funds Clinical Trials Against Aging
FDA approval is only granted to companies that develop rejuvenation biotechnology intervention products that target specific diseases. This FOA, however, is meant to encourage broader research which does not necessarily have individual diseases as an endpoint.
The National Institutes of Aging in America, an element of the National Institutes of Health (NIH), funds clinical trials that target the root causes of diseases associated with aging.
Direct funding of trials against aging
The most interesting and important part of the Funding Opportunity Announcement is the fact that the NIA mentions specifically \”multiple chronic diseases\” that are caused by the aging process, along with conventional trials that target specific downstream effects.
Source:
